News

On Friday, the FDA approved Pfizer Inc’s (NYSE:PFE) Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients ...
FDA approved the company's hemophilia B gene therapy fidanacogene elaparvovec (Beqvez) in April. Pfizer noted in a press release that results for another arm of the BASIS trial in patients with ...
Pfizer PFE announced that the FDA has approved its subcutaneously administered drug marstacimab for treating certain hemophilia patients. The drug will be marketed under the trade name Hympavzi.
(RTTNews) - Pfizer Inc. (PFE) announced Friday that the U.S. Food and Drug Administration has approved HYMPAVZI (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of ...
Hympavzi, made by Pfizer, is the first antitissue-factor pathway inhibitor to be approved for the blood-clotting disorder, as well as the first hemophilia drug to offer a once-weekly treatment ...
On Friday, the FDA approved Pfizer Inc’s (NYSE:PFE) Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients ...
Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved HYMPAVZI™ for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and ...
The FDA has approved Pfizer’s Hympavzi (marstacimab-hncq) for routine prophylaxis (RP) in adults and adolescents over 12 years of age with hemophilia A or B without inhibitors. Hympavzi is now the ...
Hympavzi, made by Pfizer, is the first antitissue-factor pathway inhibitor to be approved for the blood-clotting disorder, as well as the first hemophilia drug to offer a once-weekly treatment ...
FDA approves Pfizer’s Hympavzi for routine prophylaxis in hemophilia A and B patients, offering a once-weekly dosing via auto-injector pen. Phase 3 trial showed Hympavzi reduced bleeding rates ...